Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Erasca, Inc. (ERAS)

18.03 -1.46 (-7.49%)
At close: August 28 at 4:00:01 PM EDT
18.10 +0.07 (+0.39%)
After hours: August 28 at 7:41:28 PM EDT
Trade Erasca on Coinbase
Chart Range Bar
Loading chart for ERAS
  • Previous Close 19.49
  • Open 19.25
  • Bid 13.86 x 200
  • Ask 23.47 x 200
  • Day's Range 18.00 - 19.59
  • 52 Week Range 1.33 - 24.28
  • Volume 2,887,317
  • Avg. Volume 4,783,376
  • Market Cap (intraday) 6.306B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) -0.95
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.30

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

www.erasca.com

103

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ERAS
384.68%
S&P 500 (^GSPC)
12.65%

1-Year Return

ERAS
1,048.41%
S&P 500 (^GSPC)
18.61%

3-Year Return

ERAS
585.55%
S&P 500 (^GSPC)
73.95%

5-Year Return

ERAS
21.64%
S&P 500 (^GSPC)
71.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -183.44M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-150M
-100M
-50M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

20.00
24.30 Average
18.03 Current
33.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst B of A Securities
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 18 -> 20

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    6.82B

  • Enterprise Value

    6.60B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    18.85

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.39%

  • Return on Equity (ttm)

    -78.25%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -287.22M

  • Diluted EPS (ttm)

    -0.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    268.74M

  • Total Debt/Equity (mrq)

    12.36%

  • Levered Free Cash Flow (ttm)

    -210.46M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

18.03 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: